Matthew McManus - 01 Feb 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role: President - DGS
Signature: /s/ Andrew Nick as Attorney-in-Fact for Matthew McManus pursuant to Power of Attorney previously filed.
Issuer symbol: TECH
Transactions as of: 01 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Feb 2024, 18:35:18 UTC
Previous filing: 05 Feb 2024
Next filing: 03 Feb 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TECH	Restricted Stock Units	Award	$0	+2,888		$0.000000	2,888	01 Feb 2024	Common Stock	2,888		Direct	F1, F2
transaction	TECH	Restricted Stock Units	Award	$0	+13,861		$0.000000	13,861	01 Feb 2024	Common Stock	13,861		Direct	F1, F3
transaction	TECH	Stock Option (Right to Buy)	Award	$0	+7,951		$0.000000	7,951	01 Feb 2024	Common Stock	7,951	$68.54	Direct	F2
transaction	TECH	Stock Option (Right to Buy)	Award	$0	+15,902		$0.000000	15,902	01 Feb 2024	Common Stock	15,902	$68.54	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F2	Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F3	4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026.
F4	Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028.